Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis.
BACKGROUND
Standard treatment for stage I or non-bulky stage II diffuse large B-cell lymphoma (DLBCL) has been either a brief course of chemotherapy plus involved-field radiotherapy (IFRT) or prolonged cycles of chemotherapy. The introduction of rituximab has necessitated re-evaluation of the treatment for limited disease (LD) DLBCL.


METHODS
Thirty-nine LD DLBCL patients (median age, 52 years; range, 24-85) treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) were retrospectively analyzed. Treatment outcomes were evaluated, and toxicity, event-free survival (EFS), and overall survival (OS) were compared according to the treatment and risk factors.


RESULTS
The median follow-up duration was 34.6 months (range, 9.1-65.4). The 3-year EFS and OS were 76.0% and 86.0%, respectively. Among the 36 patients who underwent either 3-4 cycles of R-CHOP followed by IFRT (N=22) or 6-8 cycles of R-CHOP (N=14), there was no difference in the 3-year EFS (79.4% vs. 71.6%, P=0.638) and 3-year OS (85.7% vs. 92.9%, P=0.732). Severe neutropenia and neutropenic fever were more frequent in patients treated with R-CHOP alone, with 1 treatment-related mortality. Among the IFRT patients, 1 required hospital admission for IFRT-related complications. No events or deaths were reported among patients without adverse risk factors.


CONCLUSIONS
The difference in outcomes between the 2 treatment options was not significant. Analysis of treatment outcomes suggested that baseline characteristics and expected toxicities should be considered in LD DLBCL treatment. Further studies are needed to define the optimal treatment in the rituximab era.
Department of Internal Medicine, Gachon University Gil Hospital, Gachon University of Medicine and Science, Graduate School of Medicine, Incheon, Korea.
Junshik
J
Hong
Ae Jin
AJ
Kim
Jin Sun
JS
Park
Seok Ho
SH
Lee
Kyu Chan
KC
Lee
Jinny
J
Park
Sun Jin
SJ
Sym
Eun Kyung
EK
Cho
Dong Bok
DB
Shin
Jae Hoon
JH
Lee
Blood. 2003 Jul 1;102(1):324-7
12649152
J Clin Oncol. 1989 Sep;7(9):1295-302
2788716
J Clin Oncol. 2007 Mar 1;25(7):787-92
17228021
Cancer. 1983 Jul 1;52(1):1-7
6406037
J Clin Oncol. 2008 May 10;26(14):2258-63
18413640
J Clin Oncol. 2002 Jan 1;20(1):197-204
11773170
N Engl J Med. 2002 Jan 24;346(4):235-42
11807147
Ann Intern Med. 1987 Jul;107(1):25-30
3296898
Lancet Oncol. 2006 May;7(5):379-91
16648042
Cancer. 1980 Dec 1;46(11):2356-9
7002279
Radiother Oncol. 1985 Nov;4(3):211-23
3909240
N Engl J Med. 2005 Mar 24;352(12):1197-205
15788496
J Clin Oncol. 2004 Aug 1;22(15):3032-8
15210738
Ann Oncol. 1998 Jul;9(7):717-20
9739436
BMC Cancer. 2010 Jun 22;10:321
20569446
J Natl Compr Canc Netw. 2010 Mar;8(3):288-334
20202462
J Clin Oncol. 1999 Apr;17(4):1244
10561185
N Engl J Med. 1998 Jul 2;339(1):21-6
9647875
J Clin Oncol. 2004 Aug 1;22(15):2982-4
15210737
Hematology Am Soc Hematol Educ Program. 2004;:221-36
15561685